Form 8-K

8-K — Armata Pharmaceuticals, Inc.

Accession: 0001104659-26-084860

Filed: 2026-07-20

Period: 2026-07-17

CIK: 0000921114

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — tm2620782d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2620782d1_ex10-1.htm)

EX-10.2 — EXHIBIT 10.2 (tm2620782d1_ex10-2.htm)

GRAPHIC (tm2620782d1_ex10-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620782d1_8k.htm · Sequence: 1

false

0000921114

2026-07-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 17, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in

its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

5005 McConnell Avenue,

Los Angeles, California

90066

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule

12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of

the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

ARMP

NYSE

American

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 17, 2026, the Board of Directors (the “Board”)

of Armata Pharmaceuticals, Inc. (the “Company”) promoted and appointed David House as the Company’s Chief Financial

Officer, effective July 17, 2026. Mr. House previously served as the Company’s Senior Vice President, Finance and principal financial

officer since August 2024. Biographical information regarding Mr. House required by Item 401 of Regulation S-K was previously reported

in the Company’s most recent definitive proxy statement filed with the SEC on April 27, 2026.

In connection with Mr. House’s appointment

as Chief Financial Officer, the Company and Mr. House entered into an employment letter agreement, dated July 17, 2026 (the “House

Agreement”), which confirms the terms of Mr. House’s continued employment with the Company from and after the date thereof.

Pursuant to the House Agreement, Mr. House will serve as the Company’s Chief Financial Officer, reporting directly to the Company’s

Chief Executive Officer.

Pursuant to the House Agreement, Mr. House will receive an annual base

salary of $371,315, and will be eligible for a target annual bonus opportunity equal to 50% of his base salary, with the actual bonus

payable based on actual performance as determined by the Board or compensation committee. Mr. House’s annual target performance

bonus percentage is subject to increase, but not decrease, from time to time in the discretion of the Board or the compensation committee.

The House Agreement provides that Mr. House will

be eligible to receive annual equity awards pursuant to the Company’s 2016 Equity Incentive Plan or any successor plan commencing

in 2026. The House Agreement states that the current intent of the compensation committee is to provide Mr. House with an equity award

each fiscal year, commencing in 2026, with a grant date fair value of approximately $300,000, but Mr. House is not entitled to any specific

award or terms, and any such awards will vest on the same basis as equity awards granted to other senior executives in respect of any

fiscal year.

The House Agreement provides that, if the Company

terminates Mr. House’s employment without “Cause” (as defined in the House Agreement) other than due to his death or

disability, or if Mr. House resigns for “Good Reason” (as defined in the House Agreement), then, subject to his execution

of a separation agreement and general release of claims and continued compliance with his post-employment restrictive covenants, Mr. House

will continue to receive his then-current base salary for 12 months following such termination. If Mr. House experiences an involuntary

termination within one month prior to, or 12 months following, a “Change in Control” (as defined in the House Agreement),

the vesting of all of his outstanding equity awards that are subject to time-based vesting requirements will accelerate in full as of

the date of such involuntary termination or, if later, the Change in Control.

On July 17, 2026, the Company and Pierre Kyme, the Company’s

Chief Business Officer, agreed to conform the definition of “change in control” in Mr. Kyme’s Employment Letter Agreement,

dated June 1, 2024 (the “Kyme Agreement”) to the definition in the House Agreement (and other agreements with senior

executives of the Company). The Kyme Agreement remains in full force and effect in accordance with its terms with this modified definition.

The foregoing descriptions of the House Agreement

and the modification of the Kyme Agreement (the “Kyme Amendment”) do not constitute complete summaries of the terms

of the House Agreement or the Kyme Amendment and are qualified in their entirety by reference to the full text of the House Agreement

and the Kyme Amendment, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein

by reference.

- 2 -

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

10.1

Employment Letter Agreement, dated July 17, 2026, by and between Armata Pharmaceuticals, Inc. and David House.

10.2

Amendment No. 1, dated July 17, 2026, to that certain Employment Letter Agreement, dated June 1, 2024, by and between Armata Pharmaceuticals, Inc. and Pierre Kyme.

104

Cover Page Interactive Data File (embedded within Inline XBRL document)

- 3 -

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Date: July 18, 2026

Armata Pharmaceuticals, Inc.

By:

/s/ Deborah L. Birx

Name:

Deborah L. Birx, M.D.

Title:

Chief Executive Officer

(Principal Executive Officer)

- 4 -

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2620782d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

Armata Pharmaceuticals, Inc.

5005 McConnell

Ave

Los Angeles,

California 90066

July 17, 2026

Dear David:

This letter agreement (this “Agreement”)

is intended to confirm our mutual agreement with respect to your continued employment with Armata Pharmaceuticals, Inc. (the “Company”)

from and after the date hereof.

Position. You agree to serve as the Company’s Chief Financial Officer, reporting directly to the Chief Executive Officer of

the Company. You agree to devote your full business time and attention to your work for the Company. Except upon the prior written consent

of the Board of Directors of the Company (the “Board”), you will not, during your employment with the Company, (i)

accept or maintain any other employment, or (ii) engage, directly or indirectly, in any other business activity (whether or not pursued

for pecuniary advantage) that might interfere with your duties and responsibilities as a Company employee or create a conflict of interest

with the Company.

Salary. Your base salary will be paid at the annualized rate of $371,315 per year on the Company’s regular payroll dates and

subject to approved deductions and required withholdings. Your salary will be reviewed from time to time by the Board or its compensation

committee (the “Compensation Committee”) and may be adjusted in the sole discretion of the Board or the Compensation

Committee.

Bonus. You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established

by the Board or the Compensation Committee. Your annual target performance bonus for each fiscal year commencing with the 2026 fiscal

year will be equal to fifty percent (50%) of your base salary, although the amount of any payment will be dependent upon actual performance

as determined by the Board or the Compensation Committee. Generally, you must be employed by the Company through the date on which bonuses

are paid in order to be eligible to receive a bonus. Your annual performance bonus, if any, shall be paid to you at the same time as annual

bonuses are paid to other senior executives of the Company and, in all events, on or before March 15 of the year following the year to

which it relates. Your annual target performance bonus percentage is subject to increase, but not decrease, from time to time in the discretion

of the Board or the Compensation Committee.

Equity Award. You will be eligible to receive additional grants pursuant to the Company’s 2016 Equity Incentive Plan or any

successor thereto (the “Plan”) commencing in 2026. The actual size of your annual grant in respect of any fiscal year

shall be consistent with your position as the Company’s Chief Financial Officer, and the terms and conditions of any equity award

granted in any fiscal year will be determined in the sole discretion of the Board and/or the Compensation Committee. The parties hereto

acknowledge and agree that the current intent of the Compensation Committee is to provide you with an equity award each fiscal year (commencing

in 2026) with a grant date fair value of approximately $300,000, but nothing herein shall entitle you to any specific award or any specific

terms or conditions in respect of any fiscal year. Grants shall be made annually (commencing with the Company’s 2026 fiscal year)

at the same time as grants of equity are made to other senior executives of the Company. Subject to your continued employment with the

Company, any equity awards granted pursuant to this paragraph in respect of any fiscal year shall vest on the same basis as equity awards

granted to other senior executives vest in respect of such fiscal year.

Benefits. You will be eligible to participate in the benefits made generally available by the Company to its senior executives, in

accordance with the benefit plans established by the Company, and as may be amended from time to time in the Company’s sole discretion.

At-Will Employment. The Company is an “at-will” employer. Accordingly, either you or the Company may terminate the employment

relationship at any time, with or without advance notice, and with or without cause.

Termination. Upon any termination of your employment, you will be deemed to have resigned, and you hereby resign, from all offices

and directorships, if any, then held by you with the Company or any subsidiary. In the event of termination of your employment with the

Company, regardless of the reasons for such termination, the Company shall pay your base salary and accrued but unused vacation up to

and through the date of termination, less applicable payroll and tax withholdings (the “Accrued Obligations”).

Severance. You shall be eligible for the severance benefits described in this Section

In the event (i) the Company terminates your employment without Cause (as defined below and other than due to your death or disability),

or (ii) you terminate your employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such termination

or resignation constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without

regard to any alternative definition thereunder, a “Separation from Service”) (such termination or resignation, an

“Involuntary Termination”), then, in addition to the Accrued Obligations, subject to your obligations below, you shall

be entitled to receive an amount equal to twelve (12) months of your then current base salary (ignoring any decrease in base salary that

forms the basis for Good Reason), less all applicable withholdings and deductions, paid on the schedule described below (the “Severance

Pay”).

The Severance Pay is conditioned upon (i) your continuing to comply with your obligations under your PIIAs (as defined in Section 11)

during the period of time in which you are receiving the Severance Pay; (ii) your delivering to the Company an executed separation agreement

and general release of claims in favor of the Company, in a form provided by the Company, within the time period set forth therein, which

becomes effective in accordance with its terms, which shall be no later than sixty (60) days following your Separation from Service. The

Severance Pay will be paid in equal installments on the Company’s regular payroll schedule over the period outlined above following

the date of your Separation from Service; provided, however, that no payments will be made prior to the sixtieth (60th)

day following your Separation from Service. On the sixtieth (60th) day following your Separation from Service, the Company

will pay you in a lump sum the amount of the Severance Pay that you would have received on or prior to such date under the original schedule

but for the delay while waiting for the sixtieth (60th) day, with the balance of the Severance Pay being paid as originally

scheduled.

“Cause” for purposes of your Severance Pay means (i) your gross negligence or willful failure substantially to perform

your duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) your commission of any act of fraud,

embezzlement or dishonesty against the Company or any other willful misconduct that has caused or is reasonably expected to result in

material injury to the Company; (iii) your unauthorized use or disclosure of any proprietary information or trade secrets of the Company

or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv) your willful

breach of any of your obligations under any written agreement or covenant with the Company, including without limitation this Agreement

and your PIIAs.

“Good Reason” for purposes of your Severance Pay means the occurrence at any time of any of the following without your

prior written consent: (i) a material reduction in your authority, duties or responsibilities (other than a mere change in title following

any merger or consolidation of the Company with another entity); (ii) a material reduction in your base salary; or (iii) any willful failure

or willful breach by the Company of any of its material obligations under this Agreement. For purposes of this subsection, no act, or

failure to act, on the Company’s part shall be deemed “willful” unless done, or omitted to be done, by the Company not

in good faith and without reasonable belief that the Company’s act, or failure to act, was in the best interest of the Company.

In order to terminate your employment under this Agreement for Good Reason, you must (1) provide written notice to the Company within

ninety (90) days of the first occurrence of the events described above, (2) allow the Company at least thirty (30) days from receipt of

such written notice to cure such event, and (3) if such event is not reasonably cured within such period, resign from all positions you

then hold with the Company effective not later than the one hundred eightieth (180th) day after the initial occurrence of such

event.

Change in Control Acceleration. If your Involuntary Termination occurs within one (1) month prior to, or twelve (12) months following

a Change in Control, then the vesting of all of your outstanding equity awards that are subject to time-based vesting requirements shall

accelerate in full such that all such equity awards shall be deemed fully vested as of the date of such Involuntary Termination (or Change

in Control, if later). For purposes of this Agreement, the term “Change in Control” shall have the meaning ascribed

to such term in the Plan.

10.

Taxes. All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings (if any) and any

other withholdings required by any applicable jurisdiction or authorized by you.

Section 409A. The Severance Pay provided in this Agreement is intended to qualify for an exemption from application of Section

409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder

and any state law of similar effect (collectively “Section 409A”) or to comply with its requirements to the extent

necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.

Each installment of Severance Pay is a separate “payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i),

and the Severance Pay is intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections

1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and you are, upon Separation from Service,

a “specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences

under Section 409A, the timing of the Severance Pay shall be delayed until the earlier of (i) six (6) months and one day after your Separation

from Service, or (ii) your death. Except to the minimum extent that payments must be delayed because you are a “specified employee”,

all amounts of Severance Pay will be paid as soon as practicable in accordance with the schedule provided herein and in accordance with

the Company’s normal payroll practices.

Section 280G. If any payment or benefit you will or may receive from the Company or otherwise (a “280G Payment”)

would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence,

be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment pursuant

to this Agreement or otherwise (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount”

shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject

to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined

by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and

the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater

economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment

is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence,

the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for

you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the

“Pro Rata Reduction Method”).

Notwithstanding the foregoing, if the Reduction

Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that

would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the

case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the

modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis;

(B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated)

before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation”

within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning

of Section 409A.

Unless you and the Company agree on an alternative

accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date

of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged

by the Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the

Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all

expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially

reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with

detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G

Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or

the Company.

If you receive a Payment for which the Reduced

Amount was determined pursuant to clause (x) of the first paragraph of this Section 10(b) and the Internal Revenue Service determines

thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount

of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 10(b)) so that no portion of the remaining

Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first

paragraph of this Section 10(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.

11.

Other. As a condition of your employment hereunder, you agree and acknowledge that each of (i) your Employee Nondisclosure, Assignment

and Non-Solicitation Agreement with C3 Jian, Inc., a predecessor of the Company, dated July 8, 2012, and (ii) your Employee Confidential

Information and Invention Assignment Agreement with the Company, dated June 28, 2022 (each, a “PIIA” and collectively,

the “PIIAs”), remains in full force and effect, and you shall continue to comply with each PIIA. The parties hereto

acknowledge and agree that this Agreement and each PIIA shall be considered separate contracts, and the PIIAs will survive the termination

of this Agreement for any reason.

12.

Clawback Policy. By signing below, you hereby acknowledge and agree that you are, and will continue to be, subject to the Company’s

Policy for the Recovery of Erroneously Awarded Compensation (as adopted on November 9, 2023), as the same may be amended and/or restated

from time to time.

13.

Entire Agreement. This Agreement, together with your PIIAs, sets forth our entire agreement and understanding regarding the terms

of your employment with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may

not be modified in any way except in a writing signed by the Company’s Chief Executive Officer (or another duly authorized officer

of the Company) upon due authorization by the Board or the Compensation Committee and you. It shall be governed by California law, without

regard to principles of conflicts of laws.

*          *          *

(Signatures are on the following page)

IN WITNESS WHEREOF, the parties have executed this Agreement as of

the date set forth below.

Sincerely,

Armata Pharmaceuticals, Inc.

By:

/s/ Deborah Birx

Name:

Deborah Birx, M.D.

Title:

Chief Executive Officer

ACCEPTED AND AGREED:

/s/ David House

July 17, 2026

David House

Date

[Signature Page to D.

House Employment Agreement]

EX-10.2 — EXHIBIT 10.2

EX-10.2

Filename: tm2620782d1_ex10-2.htm · Sequence: 3

Exhibit 10.2

amendment

No. 1

Employment agreement

This Amendment No. 1 (this “Amendment”)

to the Employment Agreement (as defined below) is entered into as of July 17, 2026, by and between Armata Pharmaceuticals, Inc. (the “Company”)

and Pierre Kyme (the “Employee”).

WHEREAS, the Company and the Employee are parties

to that certain employment letter agreement, dated June 1, 2024 (the “Employment Agreement”), which governs the terms

of the Employee’s employment with the Company; and

WHEREAS, the Company and the Employee now desire

to amend the Employment Agreement.

NOW, THEREFORE, in consideration of the covenants

and agreements herein contained, the parties hereto hereby agree as follows:

1. Capitalized Terms. Capitalized terms that are not defined in this Amendment shall have the meanings

ascribed thereto in the Employment Agreement.

2. Amendment to Employment Agreement. Section 9 of the Employment Agreement is hereby amended

and restated in its entirety to read as follows:

“9.            Change in Control Acceleration.

If your Involuntary Termination occurs within one (1) month prior to, or twelve (12) months following a Change in Control, then the vesting

of all of your outstanding equity awards that are subject to time-based vesting requirements shall accelerate in full such that all such

equity awards shall be deemed fully vested as of the date of such Involuntary Termination (or Change in Control, if later). For purposes

of this Agreement, the term “Change in Control” shall have the meaning ascribed to such term in the Plan.”

Ratification and Confirmation. Except as specifically amended by this Amendment, the Employment Agreement is hereby ratified

and confirmed in all respects and remains valid and in full force and effect. Whenever the Employment Agreement is referred to in this

Amendment or in any other agreement, document or instrument, such reference shall be deemed to be to the Employment Agreement, as amended

by this Amendment, whether or not specific reference is made to this Amendment.

Entire Agreement. The Employment Agreement and this Amendment contain the entire understanding and agreement of the parties

hereto regarding the employment of the Employee and supersede all prior negotiations, discussions, correspondence, communications, understandings

and agreements between the parties relating to the subject matter hereof.

Governing Law. This Amendment and the performance hereof shall be construed and governed in accordance with the laws of

the State of California.

Controlling Document. In case of conflict between any of the terms and conditions of this Amendment and the Employment Agreement,

the terms and conditions of this Amendment shall control.

Acknowledgment. The Employee acknowledges (i) that the Employee has consulted with or has had the opportunity to consult

with independent counsel of the Employee’s own choice concerning this Amendment, and has been advised to do so by the Company, and

(ii) that the Employee has read and understands this Amendment, is fully aware of its legal effect, and has entered into it freely

based on the Employee’s own judgment.

Counterparts. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original but all

of which together will constitute one and the same instrument. The execution of this Amendment may be by actual signature or by signature

delivered by facsimile or by e-mail as a portable document format (.pdf) file or image file attachment.

*          *          *

IN WITNESS WHEREOF, the parties have executed this

Amendment as of the date first set forth above.

Armata PharmacueticalS, Inc.

employee

By:

/s/ Deborah Birx

/s/ Pierre Kyme

Name: Deborah Birx, M.D.

Pierre Kyme

Title: Chief Executive Officer

[Signature Page to Amendment to P. Kyme Employment Agreement]

GRAPHIC

Filename: tm2620782d1_ex10-1img001.jpg · Sequence: 7

Binary file (9382 bytes)

Download tm2620782d1_ex10-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 17, 2026

Entity File Number

001-37544

Entity Registrant Name

ARMATA PHARMACEUTICALS, INC.

Entity Central Index Key

0000921114

Entity Tax Identification Number

91-1549568

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5005 McConnell Avenue

Entity Address, City or Town

Los Angeles

Entity Address, State or Province

Entity Address, Postal Zip Code

90066

City Area Code

310

Local Phone Number

655-2928

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

ARMP

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration